Study identifier:1839IL/0070
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 2 part phase 2 trial to evaluate ZD1839 (Iressa™) & radiotherapy in patients w/locally advanced inoperable squamous cell carcinoma of the head & neck
head and neck cancer
Phase 2
No
Iressa (Gefitinib)
All
28
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|